Table 2.

Association between ambient UVR exposure and ovarian cancer

Condition on age (5 y) and state
Cancer subtypeControls, n (%)Cases, n (%)Crude OR (95% CI)Adjusted OR (95% CI)a
All cases
Lifetime UVRb
 Low501 (34.3)485 (32.3)1.001.00
 Medium464 (31.8)523 (34.9)0.92 (0.73–1.15)0.92 (0.72–1.19)
 High494 (33.9)492 (32.8)0.78 (0.60–1.02)0.81 (0.60–1.08)
Ptrend0.060.15
Average lifetime daily UVRc
 Low449 (30.8)537 (35.8)1.001.00
 Medium497 (34.1)490 (32.7)0.76 (0.62–0.94)0.86 (0.68–1.08)
 High513 (35.1)473 (31.5)0.70 (0.56–0.88)0.73 (0.57–0.95)
Ptrend0.0030.02
Invasive cases
Lifetime UVR
 Low501 (34.3)333 (27.4)1.001.00
 Medium464 (31.8)444 (36.5)0.97 (0.76–1.24)1.03 (0.79–1.36)
 High494 (33.9)438 (36.1)0.84 (0.64–1.11)0.91 (0.67–1.24)
Ptrend0.210.50
Average lifetime daily UVR
 Low449 (30.8)437 (36.0)1.001.00
 Medium497 (34.1)397 (32.7)0.78 (0.62–0.97)0.88 (0.69–1.13)
 High513 (35.1)381 (31.1)0.78 (0.61–1.00)0.82 (0.63–1.08)
Ptrend0.040.15
Borderline cases
Lifetime UVR
 Low501 (34.3)152 (53.3)1.001.00
 Medium464 (31.8)79 (27.7)0.78 (0.52–1.15)0.69 (0.45–1.06)
 High494 (33.9)54 (20.0)0.57 (0.34–0.95)0.57 (0.33–0.99)
Ptrend0.030.04
Average lifetime daily UVR
 Low449 (30.8)100 (35.1)1.001.00
 Medium497 (34.1)93 (32.6)0.67 (0.46–0.99)0.76 (0.49–1.17)
 High513 (35.1)92 (32.3)0.47 (0.31–0.71)0.51 (0.32–0.81)
Ptrend0.00030.004
  • aAdjusted for BMI last year (<25, 25–29.9, 30–34.9, 35+ kg/m2), parity (0, 1–2, 3+), ever breastfeeding (yes/no), use of hormonal contraceptive pills (never,<60, >60 months), and family history of breast/ovarian cancer.

  • bCumulative lifetime ambient UVR tertiles based on distribution of all cases and controls: lowest third, <60,338,462; middle third, 60,344,079–76,808,619; highest third, >76,813,788 J/m2.

  • cAverage lifetime daily ambient UVR tertiles: lowest, <3,059; middle, 3,059–3,583.96; highest, >3,583.97 J/m2.